SCHEMBL182866

SCHEMBL182866

CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)C(N)=NS(=O)(=O)C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
F2 P00734 4/20 0.47
PRSS1 P07477 4/20 0.47
PRSS2 P07478 4/20 0.47
PRSS3 P35030 4/20 0.47
CA14 Q9ULX7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1535717 1.00 F2 (0.47) F2PRSS1PRSS2PRSS3CA14
SCHEMBL8359852 0.78 HDAC6 (0.33)
SCHEMBL16728067 0.76 F2 (0.50) F2PRSS1PRSS2PRSS3
SCHEMBL28416564 0.73 HDAC6 (0.32)
SCHEMBL2339827 0.72 F2 (0.50) F2PRSS1PRSS2PRSS3CA14
SCHEMBL2339824 0.72 F2 (0.50) F2PRSS1PRSS2PRSS3CA14
SCHEMBL12483135 0.72 HDAC1 (0.31)
SCHEMBL6813444 0.72 HDAC1 (0.31)
Trifluoromethanesulfonic Acid SCHEMBL2352815 0.71 CA14 (0.32) F2PRSS1PRSS2PRSS3CA14
SCHEMBL15877146 0.71 CA14 (0.30) CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119019471-A Fluorine-containing cytidine guanidine compound, and preparation method and application thereof 沈阳农业大学 2024-11-26 CN claimed
CN-119019471-A Fluorine-containing cytidine guanidine compound, and preparation method and application thereof 沈阳农业大学 2024-11-26 CN disclosed
WO-2023209586-A1 GLYCOMIMETIC BINDERS FOR L-SIGN UNIVERSITÀ DEGLI STUDI DI MILANO (IT) 2023-11-02 WO disclosed
EP-3830094-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS Mutabilis (FR) 2021-06-09 EP disclosed
EP-3649146-A1 APELIN PEPTIDES AND USES THEREOF The Governors of the University of Alberta (CA) 2020-05-13 EP disclosed
WO-2020025543-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS MUTABILIS (FR) 2020-02-06 WO disclosed
WO-2019008438-A1 APELIN PEPTIDES AND USES THEREOF THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2019-01-10 WO disclosed
EP-3352753-A1 SYNTHETIC SPHINGOLIPID-LIKE MOLECULES, DRUGS, METHODS OF THEIR SYNTHESIS AND METHODS OF TREATMENT The Regents of The University of California (US) 2018-08-01 EP disclosed
EP-2751141-B1 STABLE PEPTIDE-BASED PACE4 INHIBITORS SOCPRA SCIENCES SANTE ET HUMAINES S E C (CA) 2018-03-21 EP disclosed
US-9809621-B2 Stable peptide-based PACE4 inhibitors SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) 2017-11-07 US disclosed
EP-1549670-B1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY POLYPHOR LTD (CH) 2008-04-30 EP disclosed
EP-1855672-A1 HIV PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-11-21 EP disclosed
US-20070054840-A1 Template-fixed peptidomimetics with antimicrobial activity POLYPHOR LTD. (CH) 2007-03-08 US disclosed
US-20060280796-A1 Inositol-based molecular transporters and processes for the preparation thereof POSTECH FOUNDATION (KR) 2006-12-14 US disclosed
WO-2006104646-A1 HIV PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-10-05 WO disclosed
EP-1549670-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY Polyphor Ltd. (CH) 2005-07-06 EP disclosed
WO-2004093821-A2 TREATMENT OF ANTHRAX INFECTION USING INHIBITORS OF LETHAL FACTOR PROTEASE ACTIVITY HAWAII BIOTECH, INC. (US) 2004-11-04 WO disclosed
WO-2004033489-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY POLYPHOR LTD. (CH) 2004-04-22 WO disclosed
WO-2004009666-A2 DENDRIMERS AS MOLECULAR TRANSLOCATORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2004-01-29 WO disclosed
WO-2003068807-A2 ECHINOCANDIN CYCLIC PEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060280796-A1 Inositol-based molecular transporters and processes for the preparation thereof SLC2A8, SLC2A1, SLC29A2 F2 3907/4885PRSS1 4391/4885PRSS2 4826/4885
US-20070054840-A1 Template-fixed peptidomimetics with antimicrobial activity POLL, CUTA, POLR1C F2 951/4885PRSS1 750/4885PRSS2 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.